These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8388354)

  • 1. Interactions of heparins in the vascular environment.
    Dawes J
    Haemostasis; 1993 Mar; 23 Suppl 1():212-9. PubMed ID: 8388354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma.
    Zammit A; Pepper DS; Dawes J
    Thromb Haemost; 1993 Dec; 70(6):951-8. PubMed ID: 8165617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin.
    Chan AK; Paredes N; Thong B; Chindemi P; Paes B; Berry LR; Monagle P
    Thromb Haemost; 2004 May; 91(5):1009-18. PubMed ID: 15116263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J; Stehle G; Augustin J; Zimmermann R
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
    Young E; Wells P; Holloway S; Weitz J; Hirsh J
    Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma.
    Hemker HC; Béguin S
    Haemostasis; 1990; 20 Suppl 1():81-92. PubMed ID: 1964667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rational approach to heparins.
    Hemker HC; Béguin S
    Nouv Rev Fr Hematol (1978); 1992; 34(1):5-9. PubMed ID: 1326098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative inhibition of LPS-activated human monocyte-induced thrombin generation by unfractionated heparin and low molecular weight heparins.
    Nguyên P; Rémy MG; Potron G
    Haemostasis; 1999; 29(6):301-9. PubMed ID: 10844403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of thrombin-receptors of thrombocytes for the interaction of heparins and low-molecular-weight heparin in human whole blood clotting.
    Harenberg J; Schuler M; Zimmermann R; Heptner W
    Haemostasis; 1988; 18 Suppl 3():20-2. PubMed ID: 2840370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
    Bendayan P; Boccalon H; Dupouy D; Boneu B
    Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM; Bara L; Gerotziafas GT
    Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions.
    Serra A; Esteve J; Reverter JC; Lozano M; Escolar G; Ordinas A
    Thromb Res; 1997 Aug; 87(4):405-10. PubMed ID: 9271818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
    Sandset PM; Bendz B; Hansen JB
    Haemostasis; 2000; 30 Suppl 2():48-56. PubMed ID: 11251341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The heparins and cancer: review of clinical trials and biological properties.
    Castelli R; Porro F; Tarsia P
    Vasc Med; 2004 May; 9(3):205-13. PubMed ID: 15675186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histidine-rich glycoprotein does not interfere with interactions between antithrombin III and heparin-like compounds on vascular endothelial cells.
    Shimada K; Kawamoto A; Matsubayashi K; Ozawa T
    Blood; 1989 Jan; 73(1):191-3. PubMed ID: 2910359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From unfractionated heparins to low molecular weight heparins.
    Hirsh J
    Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human endothelial cells are stimulated and vascular smooth muscle cells are inhibited in their proliferation and migration by heparins.
    Hämmerle H; Betz E; Herr D
    Vasa; 1991; 20(3):207-15. PubMed ID: 1659056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.
    Vignoli A; Marchetti M; Balducci D; Barbui T; Falanga A
    Haematologica; 2006 Feb; 91(2):207-14. PubMed ID: 16461305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.